Rosuvastatin is not harmful to the kidneys for most people taking it at standard doses. In the large JUPITER trial, kidney-related problems occurred at nearly identical rates in people taking rosuvastatin and those taking a placebo, with no meaningful difference in kidney function over time. However, the picture gets more complicated at higher doses, in people who already have kidney disease, and in specific medical situations like cardiac surgery.
What the Major Trials Show
The strongest reassurance comes from the JUPITER trial, one of the largest studies of rosuvastatin. Among participants with moderate chronic kidney disease, reported renal disorders occurred in 4.02% of those on rosuvastatin compared to 3.90% on placebo, a difference so small it was statistically meaningless. Kidney filtration rates at 12 months were actually marginally better in the rosuvastatin group. The trial did exclude people with severely elevated creatinine levels, so its findings apply mainly to people with mild to moderate kidney impairment.
A more concerning signal emerged from the STICS trial, which studied rosuvastatin given around the time of cardiac surgery. Acute kidney injury was significantly more common in patients who received rosuvastatin: 24.7% developed it compared to 19.3% on placebo. A broader analysis of 11 trials confirmed that starting statins around the time of cardiac surgery raised the risk of acute kidney injury. Most of the excess kidney injury was relatively mild (Stage 1), but incompletely resolved cases could potentially progress to chronic kidney disease. This finding is specific to the perioperative setting, where the kidneys are already under stress from surgery, anesthesia, and changes in blood flow.
The High-Dose Question
Dose matters considerably with rosuvastatin and kidney effects. Clinical trials have consistently shown that doses of 20 mg and above carry a higher incidence of proteinuria (protein in the urine) and microscopic hematuria (blood in the urine). Both are markers that the kidneys are under some degree of stress. The FDA’s own labeling for rosuvastatin notes these findings were more frequent at the 40 mg dose compared to lower doses or other statins, though the agency describes the effect as “generally transient” and “not associated with worsening renal function.”
Case reports support this pattern. In a series of five patients who developed proteinuria and hematuria on rosuvastatin, symptoms resolved within one to two weeks after switching to a different statin. That quick reversal suggests the kidney stress is functional rather than structural, meaning the drug is changing how the kidneys filter rather than permanently damaging tissue.
How Rosuvastatin Compares to Other Statins
Not all statins affect the kidneys equally, and rosuvastatin does not come out ahead on this front. The PLANET I trial compared rosuvastatin and atorvastatin head-to-head in patients with diabetes and progressive kidney disease. Despite rosuvastatin lowering cholesterol more effectively, atorvastatin at 80 mg actually reduced urinary protein excretion by about 13%, while neither dose of rosuvastatin (10 mg or 40 mg) achieved a significant reduction. More troubling, patients on rosuvastatin 40 mg experienced a significant decline in kidney filtration rate, and doubling of creatinine and acute renal failure were more common in that group.
This is a meaningful distinction for people who already have kidney disease: the statin that lowers cholesterol more aggressively is not necessarily the one that protects the kidneys best. Atorvastatin appeared to offer genuine kidney-protective effects in this population, while high-dose rosuvastatin did not.
Dose Limits for People With Kidney Disease
The FDA sets clear boundaries for rosuvastatin in people with impaired kidney function. If your creatinine clearance is below 30 (indicating severe kidney impairment), you should start at 5 mg daily and not exceed 10 mg daily. No dose adjustment is required for mild or moderate kidney impairment. Kidney impairment also raises the risk of a rare but serious side effect called rhabdomyolysis, where muscle tissue breaks down and releases proteins that can further damage the kidneys. Because of this compounding risk, people with reduced kidney function need closer monitoring for muscle symptoms like unexplained pain, tenderness, or weakness.
What to Watch For
If you’re taking rosuvastatin and a routine urinalysis shows protein or blood in your urine, that’s worth flagging. The FDA recommends considering a dose reduction if proteinuria or hematuria shows up persistently and can’t be explained by another cause. In most cases, switching to a lower dose or a different statin resolves the issue quickly.
For people with healthy kidneys taking standard doses (5 to 10 mg), rosuvastatin carries no meaningful kidney risk based on the available evidence. The concern concentrates in three specific situations: high doses of 20 mg or above, pre-existing kidney disease (especially when paired with higher doses), and the perioperative period around cardiac surgery. Outside those scenarios, rosuvastatin’s kidney safety profile is reassuring.